Insider Selling: Artivion, Inc. (NYSE:AORT) VP Sells 7,618 Shares of Stock

Artivion, Inc. (NYSE:AORT) VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Price Performance

NYSE AORT traded down $0.06 during trading hours on Wednesday, reaching $29.62. 167,598 shares of the stock traded hands, compared to its average volume of 224,405. The stock has a 50 day simple moving average of $27.17 and a two-hundred day simple moving average of $25.91. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.10. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -1,484.00 and a beta of 1.75.

Analyst Ratings Changes

Several equities analysts have recently weighed in on AORT shares. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Artivion in a research note on Friday, September 27th. Stifel Nicolaus boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. JMP Securities assumed coverage on shares of Artivion in a research note on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price objective for the company. Finally, Oppenheimer boosted their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.00.

Institutional Investors Weigh In On Artivion

A number of large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC grew its stake in shares of Artivion by 4.7% during the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after buying an additional 124,725 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after buying an additional 33,982 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Artivion by 2.9% during the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after buying an additional 46,267 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Artivion by 4.9% during the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after buying an additional 27,906 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.